Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Sponsor: Hansoh BioMedical R&D Company
Summary
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2023-05-23
Completion Date
2024-12-30
Last Updated
2024-10-09
Healthy Volunteers
Yes
Interventions
HS-10390 tablet
Oral administration of specified dose of HS-10390
Placebo tablet
Oral administration of matching dose ofplacebo
Locations (1)
Zhongda Hospital, Affiliated to Southeast University
Nanjing, Jiangsu, China